GLP-1 weight loss in Australia: what the medication class is and how access works

GLP-1 stands for glucagon-like peptide-1. It is a hormone your body makes naturally, released in response to eating, and it plays a part in how you regulate appetite and blood sugar. The medicines commonly grouped under the GLP-1 banner are known as GLP-1 receptor agonists. In simple terms, they are designed to work along the same biological pathway as that natural hormone. They are prescription medicines used within a broader, practitioner-supervised weight-management plan, not standalone products you take on your own initiative.

You will sometimes see the generic drug names semaglutide and tirzepatide in factual coverage of this category. These are ingredient and drug-class names rather than brands. Tirzepatide is often described as a dual-action medicine that works on more than one receptor, while semaglutide is one of the more established names in the GLP-1 space. We flag these only so the terminology is familiar. The important point is that these are serious prescription medicines, which is exactly why a practitioner must be involved before anyone uses them.

In Australia, GLP-1 medications are prescription-only. Under the national medicines scheduling system they sit in the category that requires a registered practitioner to authorise supply. That status reflects the fact that these medicines carry real clinical considerations: potential side effects, interactions with other medicines, and suitability that depends on your individual health history. None of that can be judged by a webpage or a marketing quiz. It requires a practitioner.

This is worth sitting with, because the online conversation around GLP-1 can make it sound like a consumer product you simply choose. It is not. Legitimate access always runs through an assessment, and the practitioner decides whether a prescription is appropriate for you. Anyone promising guaranteed access to a specific medicine before an assessment is not operating the way a compliant Australian service should.

There are two mainstream ways Australians are assessed for GLP-1 weight-management plans, and both are valid.

Your GP, in person. A regular GP can assess you with full whole-of-health context, order any tests they think are needed, and manage your care alongside anything else that is going on. It is slower to get moving and depends on appointment availability, but for many people the continuity is valuable. Our comparison of telehealth versus your GP covers the trade-off honestly.

Online telehealth. Telehealth services run an eligibility questionnaire that a registered Australian practitioner reviews. You answer detailed questions about your health, the practitioner assesses whether a plan is appropriate, and if a prescription is suitable it is arranged through a pharmacy, often with home delivery. The appeal is speed and flexibility: you can start the assessment in your own time. Moshy is one Australian telehealth service that runs this model and is open to anyone eligible. You can read how it works in our Moshy review, or see how the online pathway generally runs in our guide to the online weight-loss doctor process.

This is the single most important thing to understand about GLP-1 in Australia. Eligibility is a clinical decision. A registered practitioner reviews your individual situation and decides whether a prescription is appropriate. Completing a questionnaire is the start of that process, not the end of it, and it is not an approval. Some people are assessed and told these medicines are not suitable for them, and that outcome is the screening doing exactly what it should.

Cost is also worth understanding up front. It usually has two parts: a fee for the telehealth service or consult, and the separate cost of any medicine that is dispensed. Prices vary and change over time, and the figure is confirmed during the consult. Our guide to weight-loss telehealth cost in Australia explains how that typically works, and our page on weight-loss injections in Australia covers the injectable side of the category in more detail.